Biomarin Pharmaceutical reported $1.08B in Debt for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Debt Change
Acorda Therapeutics ACOR:US USD 187.69M 2.71M
Agios Pharmaceuticals AGIO:US USD 1.14M 84K
Alnylam Pharmaceuticals ALNY:US USD 1.02B 338.25M
Amgen AMGN:US USD 38.7B 2.18B
Bayer BAYN:GR EUR 44.79B 157M
Biogen BIIB:US USD 6.28B 998M
Biomarin Pharmaceutical BMRN:US USD 1.08B 986K
Insmed INSM:US USD 807.82M 491K
Intercept Pharmaceuticals ICPT:US USD 332.31M 381.55M
IONIS PHARMACEUT IONS:US USD 1.25B 1.34M
Moderna Inc MRNA:US USD 1.15B 384M
Neurocrine Biosciences NBIX:US USD 169.2M 200K
Ptc Therapeutics PTCT:US USD 1.06B 145.39M
Puma Biotechnology PBYI:US USD 97.99M 312K
Regeneron Pharmaceuticals REGN:US USD 2.7B 400K
Roche Holding ROG:VX 27.75B 3.45B
Sarepta Therapeutics SRPT:US USD 1.54B 441.9M
United Therapeutics UTHR:US USD 800M 0
Vertex Pharmaceuticals VRTX:US USD 442.3M 40M
YTE INCY:US USD 33.59M 605K